샘플 요청 목록

 카트 문의
시장보고서
상품코드
1842346

NUT 정중선 암 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료별, 투여 경로별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

NUT Midline Carcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Targeted Therapy), By Route Of Administration (Oral, IV), By End Use, By Region, And Segment Forecasts, 2025 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

NUT 정중선 암 치료 시장 요약

세계 NUT 정중선 암 치료 시장 규모는 2024년에 214억 4,000만 달러로 추정되며, 2033년에는 695억 3,000만 달러에 달할 것으로 예상되며, 2025년부터 2033년까지 CAGR 14.6%로 성장할 것으로 예상됩니다.

진단 및 치료법의 발전, NUT 정중선 암의 유병률 증가, 희귀 암종 퇴치를 위한 정부의 노력 등이 이러한 성장을 견인하고 있습니다.

2024년 1월 미국 국립의학도서관이 발표한 연구에 따르면, NUT 암의 유병률은 광범위하며, 자궁경부 및 두부 미분화암의 경우 17.9%-1.9%로 보고되고 있습니다. 이번 연구에서는 그동안 저분화암 또는 미분화암으로 분류된 두경부암 362건을 분석한 결과, NUT 암이 저분화암의 2.9%, 미분화암의 12.5%를 차지한다는 사실을 밝혀냈습니다.

희귀질환 의약품에 대한 우대 조치, 세액공제, 수수료 면제, 시장 독점권, 촉진 프로그램 등 유리한 규제 경로로 인해 NUT 암은 희귀암 치료제에 투자하는 소규모 생명공학 기업이나 대형 제약사에게 매력적인 대상이 되고 있습니다. 표적 치료제의 등장과 발전도 시장 성장의 원동력이 될 것으로 예상됩니다. NIH가 2024년 2월에 발표한 보고서에 따르면, 폐 NC에서 면역치료의 유용성을 강조하는 사례 보고가 있으며, 초기 임상시험에서 BET 억제제의 활성을 시사하고 있습니다. 절제 불가능한 부비동 NC를 앓고 있는 27세 여성의 획기적인 사례에서 BET 억제제 치료와 면역요법 모두 지속적인 반응을 보였습니다. 2025년 7월, Zenith Epigenetics는 ZEN-3694가 NUT 암에서 미국 FDA의 패스트트랙 지정을 받았다고 발표했으며, ZEN-3694의 희귀질환 치료제 및 획기적 치료제 지정도 추진하고 있습니다.

이들 종양의 대부분은 부비동에 발생하며(73.4%), 타액선(11.0%), 후두(4.6%), 인두 및 구강(3.7%)에 발생하는 비율이 더 적었습니다. 그러나 NUT 암은 두경부에만 국한되지 않고 골반, 신장, 폐, 췌장, 뼈 등 다양한 해부학적 부위에서 확인되고 있어 다양한 부위에서 발생할 가능성을 보여주고 있습니다. 이러한 예측할 수 없는 분포는 다른 저분화암을 모방하는 희귀한 침습성 악성 종양인 NUT 암의 실제 유병률을 진단하고 이해하는 데 있어 어려움을 강조합니다.

진단 기술이 발전함에 따라 의학계는 희귀하고 공격적인 암인 NUT 암을 정확하게 식별하고 이해할 수 있게 되었습니다. 특히 FISH(Fluorescent In Situ Hybridization)과 차세대 염기서열 분석(NGS)의 중요한 기술 혁신은 NMC 특유의 유전자 이상을 정확하게 검출함으로써 NMC 검출에 혁명을 일으켰습니다. 이러한 진단 정확도 향상은 표적 치료제 개발 및 환자 예후 개선에 필수적입니다. 역사적으로 다른 저분화암과 조직학적으로 유사하여 오진되어 왔던 NMC는 이제 이러한 정밀한 분자진단 도구의 혜택을 받아 조기 발견을 용이하게 하고 효과적인 치료 전략을 유도하는 데 필수적인 NMC를 별도의 임상적 존재로 자리매김하고 있습니다.

정확한 NUT 정중선 암(NMC) 치료의 증가는 전문 치료에 대한 수요를 크게 증가시켜 시장 확대를 촉진하고 제약회사들이 새로운 치료법에 대한 투자를 촉진하고 있습니다. 2023년 미국 국립암연구소(NCI)에 따르면 NMC 환자의 평균 생존기간은 약 10개월, 2년 생존율은 30.0%에 불과합니다. 표적치료와 면역치료 연구가 활발해지면서 인공지능(AI)과 머신러닝의 통합은 진단 프로세스에 혁명을 가져올 것입니다. 이러한 기술은 광범위한 유전자 데이터세트를 신속하게 분석하여 NMC의 검출 정확도를 높이고, 이전에 발견되지 않았던 사례를 발견하여 이 질환의 유병률에 대한 이해를 넓힐 수 있습니다. 첨단 진단과 혁신적인 치료법의 조합은 NUT 암과의 싸움에서 중요한 진전입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 NUT 정중선 암 치료 시장 변수, 동향, 범위

  • 시장 계통 전망
  • 시장 역학
  • NUT 정중선 암 치료 시장 분석 툴
    • 업계 분석 - Porter's Five Forces 분석
    • PESTEL 분석
  • NUT 정중선 암 치료 시장 : 파이프라인 분석

제4장 NUT 정중선 암 치료 시장 : 치료 추정·동향 분석

  • 치료 부문 대시보드
  • NUT 정중선 암 치료 시장 : 치료 변동 분석
  • 세계의 NUT 정중선 암 치료 시장 규모와 동향 분석(치료별, 2021-2033년)
  • 화학요법
  • 표적요법
  • 면역요법
  • 방사선 치료
  • 기타

제5장 NUT 정중선 암 치료 시장 : 투여 경로 추정·동향 분석

  • 투여 경로 부문 대시보드
  • NUT 정중선 암 치료 시장 : 투여 경로 변동 분석
  • NUT 정중선 암 치료 시장 규모와 동향 분석(투여 경로별, 2021-2033년)
  • 경구
  • 정맥내
  • 기타

제6장 NUT 정중선 암 치료 시장 : 최종 용도 추정·동향 분석

  • 최종 용도 부문 대시보드
  • NUT 정중선 암 치료 시장 : 최종 용도 변동 분석
  • 세계의 NUT 정중선 암 치료 시장 규모와 동향 분석(최종 용도별, 2021-2033년)
  • 병원
  • 전문 클리닉
  • 기타

제7장 NUT 정중선 암 치료 시장 : 지역 추정·동향 분석

  • 지역 시장 대시보드
  • 지역별 시장 점유율 분석, 2024년 및 2030년
  • NUT 정중선 암 치료(지역별) 주요 포인트
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 노르웨이
    • 스웨덴
    • 덴마크
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트

제8장 경쟁 구도

  • 주요 시장 진입 기업의 최근 동향과 영향 분석
  • 기업/경쟁 분류
  • 벤더 상황
    • Key company heat map analysis, 2024
  • 기업 개요
    • Merck & Co. Inc
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • C4 Therapeutics, Inc.
    • Ipsen Biopharmaceuticals, Inc.
    • GSK plc
KSM 25.10.30

NUT Midline Carcinoma Treatment Market Summary

The global NUT midline carcinoma treatment market size was estimated at USD 21.44 billion in 2024 and is projected to reach USD 69.53 billion by 2033, growing at a CAGR of 14.6% from 2025 to 2033. Advancements in diagnostics and therapeutics, the rising prevalence of the NUT midline carcinoma, and government initiatives to combat rare cancer types drive this growth.

According to a study published by the National Library of Medicine in January 2024, the prevalence of NUT carcinoma varies widely, reported between 17.9% and 1.9% in undifferentiated neck and head carcinomas. The study analyzed 362 cases previously classified as poorly differentiated or undifferentiated carcinomas of the head and neck, revealing that NUT carcinoma accounted for 2.9% of poorly differentiated and 12.5% of undifferentiated cases.

Orphan-drug incentives and favorable regulatory pathways, such as tax credits, fee waivers, market exclusivity, and accelerated programs, make NUT carcinoma an attractive target for small biotech and big pharmaceutical companies investing in rare-cancer drugs. Emergence and advances in targeted therapies are also expected to drive market growth. According to a report published by NIH in February 2024, the case reports highlight the benefit from immunotherapy in lung NCs, and early trials suggest activity of BET inhibitors. A landmark case of a 27-year-old woman with unresectable sinonasal NC demonstrated a sustained response to both BET inhibitor therapy and immunotherapy. In July 2025, Zenith Epigenetics announced that ZEN-3694 was granted U.S. FDA Fast Track Designation in NUT Carcinoma, and the organization was also pursuing Orphan Drug and Breakthrough Therapy designations for ZEN-3694.

Most of these tumors were located in the sinonasal tract (73.4%), with smaller percentages found in the salivary gland (11.0%), (4.6%), larynx (7.3%), pharynx and oral cavity (3.7%). However, NUT carcinoma is not confined to the head and neck region; it has been identified in various other anatomical sites, including the pelvis, kidney, lung, pancreas, and bone, demonstrating its potential to arise in diverse locations. This unpredictable distribution underscores the challenges in diagnosing and understanding the true prevalence of NUT carcinoma, a rare and aggressive malignancy that often mimics other poorly differentiated carcinomas.

As diagnostic techniques advance, the medical community is increasingly able to accurately identify and understand NUT carcinoma, a rare and aggressive cancer. Significant innovations, particularly in fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS), have revolutionized the detection of NMC by pinpointing its unique genetic abnormalities. This improved accuracy in diagnosis is critical for developing targeted therapies and enhancing patient outcomes. Historically misdiagnosed due to its histological similarities to other poorly differentiated carcinomas, NMC now benefits from these precise molecular diagnostic tools, which facilitate earlier detection and establish NMC as a distinct clinical entity, essential for guiding effective treatment strategies.

The rise in accurate NUT midline carcinoma (NMC) diagnosis has significantly increased the demand for specialized treatments, driving market expansion and encouraging pharmaceutical companies to invest in novel therapies. According to the National Cancer Institute (NCI) in 2023, the average survival for NMC patients is around 10 months, with a 2-year survival rate of only 30.0%. As research into targeted therapies and immunotherapies gains momentum, integrating artificial intelligence (AI) and machine learning revolutionizes diagnostic processes. These technologies enhance the accuracy of NMC detection by swiftly analyzing extensive genetic datasets, uncovering previously undetected cases, and expanding our understanding of the disease's prevalence. This combination of advanced diagnostics and innovative treatments represents a critical advancement in the battle against NUT carcinoma.

Global NUT Midline Carcinoma Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global NUT midline carcinoma treatment market report based on treatment, route of administration, end use, and region:

  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Radiation Therapy
  • Others
  • Route Of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Intravenous (IV)
  • Other
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Specialty Clinics
  • Other
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Route of Administration
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment outlook
    • 2.2.2. Route of administration outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. NUT Midline Carcinoma Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
  • 3.3. NUT Midline Carcinoma Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. NUT Midline Carcinoma Treatment Market: Pipeline Analysis

Chapter 4. NUT Midline Carcinoma Treatment Market: Treatment Estimates & Trend Analysis

  • 4.1. Treatment Segment Dashboard
  • 4.2. NUT Midline Carcinoma Treatment Market: Treatment Movement Analysis
  • 4.3. Global NUT Midline Carcinoma Treatment Market Size & Trend Analysis, by Treatment, 2021 - 2033 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5. Targeted Therapy
    • 4.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7. Radiation Therapy
    • 4.7.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. NUT Midline Carcinoma Treatment Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Route of Administration Segment Dashboard
  • 5.2. NUT Midline Carcinoma Treatment Market: Route of Administration Movement Analysis
  • 5.3. NUT Midline Carcinoma Treatment Market Size & Trend Analysis, by Route of Administration, 2021 - 2033 (USD Million)
  • 5.4. Oral
    • 5.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5. Intravenous
    • 5.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.6. Other
    • 5.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. NUT Midline Carcinoma Treatment Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Segment Dashboard
  • 6.2. NUT Midline Carcinoma Treatment Market: End Use Movement Analysis
  • 6.3. Global NUT Midline Carcinoma Treatment Market Size & Trend Analysis, by End Use, 2021 - 2033 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5. Specialty Clinics
    • 6.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. NUT Midline Carcinoma Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2030
  • 7.3. NUT Midline Carcinoma Treatment by Region: Key Takeaways
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Mexico
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. UK market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. France market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Norway
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Norway market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Sweden
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Regulatory framework/ reimbursement structure
      • 7.5.7.3. Competitive scenario
      • 7.5.7.4. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Regulatory framework/ reimbursement structure
      • 7.5.8.3. Competitive scenario
      • 7.5.8.4. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. China market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. India market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. Thailand
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. Kuwait
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Regulatory framework/ reimbursement structure
      • 7.8.4.3. Competitive scenario
      • 7.8.4.4. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. Merck & Co. Inc
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Bristol-Myers Squibb Company
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Pfizer Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. F. Hoffmann-La Roche Ltd
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. C4 Therapeutics, Inc.
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Ipsen Biopharmaceuticals, Inc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. GSK plc
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제